Papers & Updates

To identify new therapies for STK11-mutant lung cancer resistant to anti-PD-1, CRISPR screens revealed that loss of MGAT1, a glycosyltransferase, restored anti-PD-1 sensitivity by enhancing T-cell mediated tumor killing. Leveraging this, the researchers developed potent, allosteric small-molecule inhibitors of MGAT1 through high-throughput screening and medicinal chemistry, establishing MGAT1 as a druggable target for immune evasion.

This real-world study retrospectively analyzed 17 advanced epithelioid sarcoma (ES) patients treated with tazemetostat to re-validate EZH2 as a therapeutic target, addressing uncertainty following the drug's global withdrawal due to safety concerns. The research demonstrated significant antitumor activity, including an overall response rate of 37.5% (44.4% for monotherapy) and a disease control rate of 93.8%, alongside a favorable safety profile (all AEs grade 1-2). These findings support EZH2 as a biologically relevant target, underscoring the potential for developing next-generation inhibitors for ES.

Researchers developed a complex-targeted strategy using covalent molecular glues to inhibit Rho GTPase signaling. Through fragment screening, they discovered inhibitors RS-009 and MC-278 that bind and stabilize a non-productive Kalirin-Rac1 GEF-GTPase complex. This mechanism traps Kalirin and reduces nucleotide exchange, offering a novel, selective approach for targeting GTPase signaling with potential as chemical probes or therapeutics.

This study elucidated the molecular basis of butylated hydroxytoluene (BHT) lung toxicity, identifying alveolar type 1 cell-specific cytochrome P450 2B10 (CYP2B10) as the enzyme responsible for its bioactivation. Using single-cell transcriptomics, cell culture, and proteomic experiments, researchers demonstrated that CYP2B10 converts BHT into a toxic quinone methide, leading to protein alkylation, DNA damage, and apoptosis, thereby explaining BHT's injurious effects.

This research investigated the structure-activity relationship of calanthoside, an indole S,O-bisdesmoside more effective than minoxidil at promoting human hair follicle dermal papilla cell proliferation. By synthesizing and evaluating ten indole-substituted analogues, the study identified the 5-chloro analogue (13b) as having markedly enhanced proliferative activity, highlighting the specific beneficial effect of 5-chlorination.

Oligo(ethylene glycol)-ketone copolymers were synthesized via RAFT polymerization and developed as recyclable catalysts for the mild, *in situ* dioxirane-mediated epoxidation of alkenes. The study revealed that copolymer composition significantly influences dioxirane intermediate formation and overall reaction efficiency. Crucially, the OEG side chains enable efficient epoxide product extraction and facilitate ketone catalyst recycling.

This paper advocates for the implementation of drug repurposing and secondary pharmaceutical combinations strategies.

This research evaluated the Multi4 instrument for outpatient management of recurrent non-muscle-invasive bladder cancer (NMIBC) under local anesthesia. Preclinical studies confirmed its safety and ability to provide high-quality biopsies, while a first-in-human clinical investigation in 18 patients showed 92% of biopsies were evaluable with an 89% diagnostic yield and minimal patient discomfort (median pain 0.5/10). The Multi4 enables feasible, safe, and reliable outpatient biopsy and lesion management, significantly reducing per-procedure costs by 73-89% compared to standard surgical resection.

This review summarizes a decade of research on coumarin derivatives as promising antibacterial agents, which combat resistance by targeting bacterial DNA gyrase and topoisomerase IV. It details how rational structural modifications, supported by computational modeling of binding interactions, significantly enhance their enzyme inhibition, antibacterial potency, and dual-target activity, establishing coumarin as a versatile scaffold for next-generation therapeutics.

This research isolated numerous novel polybenzyls from *Gastrodia elata*, demonstrating their formation through structural modification during traditional processing and decocting methods. Bioassays revealed these formed polybenzyls possess significantly higher activity compared to the plant's main constituents. These findings provide a medicinal chemistry basis for why *G. elata* is processed traditionally in TCM, showing how these methods optimize active compounds.

This research investigated metallophthalocyanine-based 2D conductive metal-organic frameworks (cMOFs) with synergistic dual-metal active sites (M1Pc-O-M2) as bifunctional electrocatalysts for efficient glycerol oxidation (GOR) and hydrogen evolution. NiPc-O-Ni emerged as the superior catalyst, exhibiting high GOR activity (10 mA cm-2 at 1.33 V, 71% formate selectivity) and enabling glycerol-assisted electrolysis with a significantly reduced cell voltage (1.99 V at 10 mA cm-2, 230 mV lower than water splitting). This work establishes clear structure-activity relationships, demonstrating the promise of rationally designed 2D cMOFs for coupling biomass valorization with hydrogen production through cooperative dual-metal sites.

In a Phase III trial comparing trastuzumab botidotin with trastuzumab emtansine for HER2-positive advanced breast cancer patients previously treated with trastuzumab and a taxane, trastuzumab botidotin significantly extended progression-free survival (median 11.1 vs 4.4 months; HR 0.39, P < .0001). This novel antibody-drug conjugate also achieved a higher objective response rate (76.9% vs 53.0%) and presented a distinct safety profile, notably with manageable ocular adverse events.

In a first-in-human clinical trial, researchers investigated glycocalyx-edited autologous mesenchymal stem/stromal cells (MSCs), modified to express sialylated Lewis X for enhanced bone-homing, in ten women with advanced osteoporosis. A single intravenous infusion of these cells safely and durably reduced fragility fractures, while increasing osteoanabolic bone turnover markers, bone tissue area, and volumetric bone mineral density. These findings demonstrate that glycocalyx editing effectively enables MSC-based osteoporosis therapy, even with cells derived from older, diseased individuals.

This study developed a mutation-agnostic, RHO-specific approach using adeno-associated viral vector-mediated homology-independent targeted integration (AAV-HITI) to treat dominant Retinitis Pigmentosa (ADRP). By optimizing donor DNA for targeted integration into the endogenous RHO locus, the method significantly improved retinal structure, function, and visual acuity for up to a year in a humanized RP4 mouse model. These findings establish AAV-HITI as an effective, human-centric platform for ADRP and other dominant genetic conditions.

This phase 1b study investigated iza-bren, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in 162 heavily pretreated patients with locally advanced or metastatic breast cancer across three subtypes (HER2-positive, HR+/HER2-negative, and TNBC). The drug exhibited a generally tolerable safety profile, despite common hematologic toxicities and two treatment-related deaths, and demonstrated clinically meaningful objective response rates ranging from 34.8% to 46.3% across all three difficult-to-treat patient groups.

This Phase 1a clinical trial evaluated the safety, pharmacokinetics, and pharmacodynamics of XRD-0394, a dual ATM/DNA-PK inhibitor, administered as a single dose with palliative radiotherapy. The study found no dose-limiting toxicities and only mild adverse events, with the 160 mg dose achieving prespecified target plasma exposures, thus supporting its safe combination with radiotherapy and further multi-dose development.

This study designed and synthesized novel tryptamine derivatives, evaluating their antifungal activity against *Podosphaera xanthii*, which causes cucurbit powdery mildew. Compounds 13h and 5o exhibited excellent curative effects comparable to commercial fungicide difenoconazole, with 13h specifically shown via microscopy to induce severe hyphal breakage, cellular integrity loss, and organelle damage, thereby establishing critical structure-activity relationships for developing new tryptamine-based antifungal agents.

This study engineered GMP-compatible dual-antigen and monocistronic AdV5 vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV). In mouse models, these formulations elicited robust Th1-polarized humoral and cellular immune responses, conferring 100% protection against lethal challenge and significant viral clearance, suggesting multiple protective immune mechanisms. These findings strongly support the advancement of AdV5-based CCHFV vaccines for further clinical development.

This study evaluated the expression of five antibody-drug conjugate (ADC) targets (CLDN18.2, c-MET, Nectin-4, TROP2, HER2) by immunohistochemistry in resected primary and metastatic biliary tract cancer (BTC) samples, finding frequent but heterogeneous expression for most targets. Significantly, discordance in target expression was observed between paired primary and metastatic tumors, and no association was found between target expression and genomic alterations or survival outcomes. These findings highlight complexities in target quantification and sampling, suggesting challenges for ADC therapy in BTC.

A meta-epidemiological analysis of 21 randomized antibody-drug conjugate (ADC) trials for metastatic breast cancer revealed that treatment effects on progression-free survival (PFS) consistently exceeded those on overall survival (OS). Using a ratio of hazard ratios (rHR = HR_PFS/HR_OS), researchers found a pooled rHR of 0.79, indicating a larger relative benefit on PFS. Although effect directions were largely concordant, 24% of trials showed a significant PFS benefit without OS improvement, suggesting PFS is an imperfect surrogate for OS in this context.